Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects.
Julia Kang, Maria Lechuga, Jenna Braun and 3 others
PMID 34753152WHAT IT FOUND
Teprotumumab infusions require checks before each dose: glucose, pregnancy test when applicable, side-effect review, and 30 minutes observation; high glucose or bloody diarrhea means delay or evaluation.
Key findings
01The guideline quotes trial data: 171 patients were randomized to teprotumumab or placebo. In those reports, 83% of teprotumumab treated subjects had proptosis improvement of at least 2 mm at 24 weeks versus 10% on placebo. Diplopia improved by at least 1 grade in 68% versus 29% on placebo, and 53% had complete resolution at 24 weeks.
02Side effects were reported in 85% of teprotumumab patients versus 69% of placebo patients, mostly grade 1 or 2. Common events included muscle spasms (30%), alopecia (20%), hyperglycemia (10%), diarrhea (10%), fatigue, headache, and hearing impairment (10%). Infusion reactions were reported in approximately 4% of patients, were usually mild or moderate, and can usually be managed with corticosteroids and antihistamines.
03The guideline directs infusion centers to record weight and obtain metabolic panel, HgA1c, risk questionnaire, and pregnancy test when applicable before the first infusion; observe patients for 30 minutes after infusion; review glucose and labs with the prescribing physician; delay if glucose is too high; and question patients about side effects before each infusion, with no further infusion for persistent diarrhea, especially bloody, until full evaluation. It also describes home infusion only after the first 2 doses are well-tolerated.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a guideline article, not a new study with participants. It does not describe how the cited trial reports were selected or appraised. Several authors have ties to the manufacturer, Horizon Therapeutics. The guideline notes teprotumumab is not approved for pregnant or lactating women and pediatric safety has not been established, so it does not apply to those groups. Home infusion is mentioned only after initial doses are well-tolerated, and the article does not report outcomes from home administration.
Declared interests
K Cockerham and R Douglas are on the Horizon Therapeutics Medical Advisory Board. A Kossler is a consultant for Horizon Therapeutics. M Lechuga and J Braun have no conflicts of interest to disclose.
The easy way to misread this
Do not read the case reports of optic neuropathy improvement as proof that teprotumumab reliably restores vision. The guideline says those are case reports, and it notes the medication is not approved for pregnant or lactating women or children, and requires caution with uncontrolled diabetes or inflammatory bowel disease.